Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium–glucose cotransporter 2 inhibitor

Fig. 2

Long-term body weight (BW) trajectories across study groups. The log-term BW trajectories for the five study groups of different baseline BMI categories receiving SGLT2i treatment remained stable from 3 months onward in all study groups, and there is no difference of the BW slope across 5 study groups (P: 0.712) (a). The respective mean (SE) BW changes from baseline to the 3 months following-up in these 3 groups of different BW-loss categories following SGLT2i treatment were 1.4 (0.04), − 2.1 (0.14), and − 5.9 (0.08) kg. The mean (SE) BW slope from 3 months until the last available measurements among participants receiving SGLT2i was − 0.67 (− 0.50), − 0.14 (− 0.13), and 0.85 (0.23) kg/year in these 3 groups. There is significant difference of the BW slope across 3 study groups (P = 0.046) (b). BMI: body mass index; BW: body weight; SE: standard error; SGLT2i: sodium–glucose cotransporter 2 inhibitors

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840